Denileukin diftitox

Denileukin diftitox (trade name Ontak) was an antineoplastic agent, an engineered protein combining Interleukin-2 and Diphtheria toxin. Denileukin diftitox could bind to Interleukin-2 receptors[1] and introduce the diphtheria toxin into cells that express those receptors, killing the cells. In some Leukemias and Lymphomas malignant cells express these receptors, so denileukin diftitox can target these.

Denileukin diftitox
Clinical data
Trade namesOntak
AHFS/Drugs.comMonograph
MedlinePlusa611024
Pregnancy
category
  • US: C (Risk not ruled out)
    Routes of
    administration    		Intravenous
    ATC code
    Legal status
    Legal status
    Pharmacokinetic data
    Elimination half-life70-80 min
    Identifiers
    CAS Number
    IUPHAR/BPS
    DrugBank
    ChemSpider
    • none
    UNII
    ChEMBL
    Chemical and physical data
    FormulaC2560H4042N678O799S17
    Molar mass57647.3 g/mol g·mol−1
     NY (what is this?)  (verify)

    In 1999 Ontak was approved by the U.S. Food and Drug Administration (FDA) for treatment of Cutaneous T-cell lymphoma (CTCL).[2]

    There is some evidence tying it to vision loss and in 2006 the FDA added a black box warning to the drug's label.[2]

    In 2014 marketing of Ontak was discontinued in the US.[3]

    References
    1. Turturro F (2007). "Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders". Expert Rev Anticancer Ther. 7 (1): 11–7. doi:10.1586/14737140.7.1.11. PMID 17187516.
    2. FDA Page Last Updated: May 11, 2009 Changes in the Ontak (denileukin diftitiox) Package Insert to Include a Description of Ophthalmologic Adverse Events
    3. "FDA Drug Shortages". FDA. 31 January 2014. Retrieved 3 July 2017.


    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.